Glimivex-M1 Forte Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 1000mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The sustained-release formulation ensures a gradual release of metformin, minimizing gastrointestinal side effects commonly associated with immediate-release forms and improving patient compliance. Glimivex-M1 Forte is indicated as an adjunct to diet and exercise to improve glycemic control in adults whose diabetes is inadequately controlled by either metformin or glimepiride monotherapy. It is essential to monitor renal function prior to and during treatment, as metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea, vomiting, and diarrhea, and rarely, lactic acidosis. This medication should be used under medical supervision with regular monitoring of blood glucose levels to optimize therapeutic outcomes and minimize risks.